Arthritis news and arthritis widget

A team of researchers at Keele University in Staffordshire, UK, are hoping to improve the care and treatment of painful osteoarthritis offered by GPs in a major project involving almost 2,000 local patients. The study is being funded by a five-year grant of more than £788,000 from the Arthritis Research Campaign.

Actelion Ltd (SWX: ATLN) announced that Actelion and Roche have jointly agreed that preclinical and clinical data support progressing Actelion's S1P1 receptor agonist into Phase II clinical development. An update will be presented at Actelion Day 2009, an event held at Actelion's headquarters in Allschwil on 19 February 2009. This event will be a combination of Actelion's annual Media and Analyst Conference and its Research and Development Day.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.

HealthDay - THURSDAY, Nov. 13 (HealthDay News) -- New understanding about how to control autoimmune responses offers promise in efforts to develop treatments for rheumatoid arthritis (RA), British researchers say.

Title: Rheumatoid Arthritis Pictures SlideshowCategory: SlideshowsCreated: 11/10/2008Last Editorial review: 11/13/2008

Use of Latin prescription abbreviations has become a kind of medical shorthand. However, unless you have a medical background, prescription abbreviations can be hard to follow. What do the prescription abbreviations mean?

Several arthritis medications have been marketed since 1998. How much do you know about arthritis medications? Take the quiz.

Should you buy cheaper Canada drugs? The FDA, drugmakers, and others are warning against reimportation of canada drugs.

Pseudogout is a type of arthritis that is often mistaken for gout or other arthritic conditions. Proper diagnosis of pseudogout is important. Here are 10 facts you should know about pseudogout.

Orencia (abatacept) is the first T-cell co-stimulation modulator approved for the treatment of rheumatoid arthritis.